CleveXel Pharma is licensing two patents relating to diagnosis and treatment of myelodysplasia and leukaemia.
Satt Sud Est is granting a license for two patents to CleveXel Pharma, a French biotech focused on oncology, diseases of the central nervous system and immuno-inflammation. The patents, one for diagnosis and one for treatment, relate to myelodysplasia and acute myeloid leukaemia.
The diagnostic patent is held by the University Hospital Nice, Nice Sophia Antipolis University and the French Institute of Health and Medical Research. The treatment patent is also held by Nice Sophia Antipolis University and the French Institute of Health and Medical Research as well as the French National Centre for Scientific Research.
The license means CleveXel Pharma will work together with the researchers at the two universities until clinical trials begin. Satt Sud Est supported the molecules’ development with €260,000 ($330,000).
Myelodysplasia is a haematological condition which means the body’s production of a certain class of white blood cells, called myeloid, is ineffective. Patients can suffer from anaemia and require blood transfusions and if the disease worsens suffer from progressive bone marrow failure. Acute myeloid leukaemia is caused by rapid growth of abnormal white blood cells which accumulate in the bone marrow, disrupting the normal production of blood cells.
Patrick Auberger, director at Nice Sophia Antipolis University’s Mediterranean Centre of Molecular Medicine, said: “Thanks to the support of Satt Sud Est, this exclusive license with CleveXel Pharma represents a unique opportunity for collaboration. Their goal is to optimise our molecules and accompanying diagnostic test with a view of running clinical trials which we are aiming to achieve as fast as possible.” [translated from French by Global University Venturing]
